CELC - Celcuity Inc.

112.18
4.780   4.261%

Share volume: 733,256
Last Updated: 03-04-2026
Healthcare/Services – Health: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$107.40
4.78
0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 25%
Dept financing 1%
Liquidity 50%
Performance 45%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.58%
1 Month
7.58%
3 Months
6.20%
6 Months
101.45%
1 Year
984.91%
2 Year
516.37%
Key data
Stock price
$112.18
P/E Ratio 
0.00
DAY RANGE
$106.78 - $112.50
EPS 
-$3.52
52 WEEK RANGE
$7.58 - $120.32
52 WEEK CHANGE
$1,024.05
MARKET CAP 
2.096 B
YIELD 
N/A
SHARES OUTSTANDING 
46.271 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-13-2025
BETA 
1.38
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$496,903
AVERAGE 30 VOLUME 
$630,097
Company detail
CEO: Brian F. Sullivan
Region: US
Website: celcuity.com
Employees: 40
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Healthcare/Services – Health
Sector: Services

Celcuity Inc. focuses on the development of molecularly targeted therapies for cancer patients in the United States. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3k signaling activity in breast and ovarian tumor cells.

Recent news